With vaccines evolving in the opposite fight to covid-19, said German glass manufacturer SCHOTT AG is in the process of supplying vials to contain up to two billion doses of vaccination.Packaging and pharmaceutical glass specialist has entered into agreements with leading pharmaceutical companies, adding players in India.
The agreements came into force last month and the roads are already being delivered to corporations in Asia, North America and Europe, the company said.
In India, SCHOTT’s 50-50 joint venture, SCHOTT KAISHA, sends vials of Covid-19 vaccine materials to the Serum Institute (India) and several other stakeholders. The joint venture operates 4 production plants in the country in Jambusar and Umarsadi in Gujarat, Daman and Baddi in Himachal Pradesh.
The specialty glass company said it can respond to the complicated scenario since it introduced a $1 billion investment program into its pharmaceutical business in 2019. “In India, this includes a three-digit figure of one million euros for the new borosilicate of glass fusion tanks, and for its packaging operations a new logo production site, as well as new modules and lines.”
SCHOTT’s 20 production sites for glass and pharmaceutical packaging are validated through regulators and pharmaceutical companies. This means that additional features can be used without delay and without additional regulatory effort. “Even before the expansions, SCHOTT was already generating more than 11 billion international pharmaceutical cases for life-saving drugs in line with the year, a nine-figure figure that is manufactured locally in India,” the company said.
“SCHOTT KAISHA is known to evolve incredibly to meet the demands of visitors over the past decade, which is also evident in its two new services in Umarsadi and Baddi.Thanks to our strong supply chain and the help of SCHOTT’s global sites, we are in a smart position to meet the existing and expected desires of our visitors.We are convinced that we can expand our production capacity in case of demand,” said Rishad Dadachanji, Director of SCHOTT KAISHA.
More importantly, all primary pharmaceutical corporations and many other market players have been processing the company’s vials on their filling and arrival lines for many years. “Therefore, no tedious adaptation of filling and filling devices will slow down the distribution of vaccines. Time is a luxury that the industry doesn’t have at the moment, so it makes sense to rely on the packaging solutions shown,” he added.
Existing users, log in here
Access Hindu Businessline content on desktops, tablets, and mobile devices.
Gain a diverse set of knowledge from our experts in portfolio, banking, economics, environment, and more.
Discover an ad-free cleaner with faster charging times.
Customize your personal tastes and get personalized advice on your interest.
Existing users, log in here
More